Acta Neuropathologica

, Volume 130, Issue 1, pp 119–129 | Cite as

Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation

  • Natalie Matosin
  • Francesca Fernandez-Enright
  • Samantha Jane Fung
  • Jeremy Stephen Lum
  • Martin Engel
  • Jessica Lee Andrews
  • Xu-Feng Huang
  • Cynthia Shannon Weickert
  • Kelly Anne NewellEmail author
Original Paper


Knockout of genes encoding metabotropic glutamate receptor 5 (mGluR5) or its endogenous regulators, such as Norbin, induce a schizophrenia-like phenotype in rodents, suggesting dysregulation of mGluR5 in schizophrenia. Human genetic and pharmacological animal studies support this hypothesis, but no studies have explored mGluR5 dysfunction at the molecular level in the postmortem schizophrenia brain. We assessed mGluR5 mRNA and protein levels in the dorsolateral prefrontal cortex (DLPFC) using a large cohort of schizophrenia and control subjects (n = 37/group), and additionally measured protein levels of recently discovered mGluR5 endogenous regulators, Norbin (neurochondrin), Tamalin (GRASP-1), and Preso1 (FRMPD4), which regulate mGluR5 localization, internalization and signaling. While mGluR5 mRNA expression was unchanged, mGluR5 protein levels were significantly higher in schizophrenia subjects compared to controls (total: +22 %; dimer: +54 %; p < 0.001). Conversely, mGluR5 regulatory proteins were expressed at lower levels in schizophrenia subjects compared to controls (Norbin −37 %, p < 0.001; Tamalin −30 %, p = 0.084; Preso1 −29 %, p = 0.001). mGluR5 protein was significantly associated with mGluR5 mRNA and mGluR5 endogenous regulators in control subjects, but these associations were lost in schizophrenia subjects. Lastly, there were no associations between protein measures and lifetime antipsychotic history in schizophrenia subjects. To confirm no antipsychotic influence, all proteins were measured in the prefrontal cortex of rats exposed to haloperidol or olanzapine; there were no effects of antipsychotic drug treatment on mGluR5, Norbin, Tamalin or Preso1. The results from our study provide compelling evidence that mGluR5 regulation is altered in schizophrenia, likely contributing to the altered glutamatergic signaling that is associated with the disorder.


Metabotropic glutamate receptor GRM5 Immunoblot Human brain Schizophrenia Antipsychotic 



Postmortem brain tissues were received from the NSW Tissue Resource Centre, which is supported by the National Health and Medical Research Council of Australia, Schizophrenia Research Institute and the National Institute of Alcohol Abuse and Alcoholism [NIH (NIAA) R24AA012725]. The authors wish to thank the Schizophrenia Research Laboratory for preparation of the human brain tissue samples, Jiamei Lian, Hongqin Wang, Kiefer Zhang and Meng He for their assistance with the animal antipsychotic drug treatment and brain sampling, and Shan-Yuan Tsai for assistance with the qRT-PCR analyses. Cynthia Shannon Weickert was supported by the University of New South Wales, Neuroscience Research Australia and the Schizophrenia Research Institute (utilizing infrastructure funding from the NSW Ministry of Health and the Macquarie Group Foundation). Cynthia Shannon Weickert is a recipient of a National Health and Medical Research Council (Australia) Senior Research Fellowship (#1021970). This study was supported by the Schizophrenia Research Institute, utilizing infrastructure funding from the NSW Ministry of Health. The animal antipsychotic drug study was supported by a National Health and Medical Research Council grant to Xu-Feng Huang (Grant ID 635231). Natalie Matosin, Jeremy S. Lum and Jessica L. Andrews are supported by Ian Scott Scholarships from Australian Rotary Health.

Supplementary material

401_2015_1411_MOESM1_ESM.docx (32 kb)
Supplementary material 1 (DOCX 32 kb)
401_2015_1411_MOESM2_ESM.jpg (175 kb)
Supplementary material 2 (JPEG 175 kb)


  1. 1.
    Beneyto M, Meador-Woodruff JH (2007) Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 33:2175–2186PubMedCrossRefGoogle Scholar
  2. 2.
    Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, Fillman SG, Rothmond DA, Sinclair D, Tiwari Y, Tsai S-Y, Weickert TW, Shannon Weickert C (2013) Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci 7:60PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F (2007) Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry 62:747–755PubMedCrossRefGoogle Scholar
  4. 4.
    Corti C, Xuereb JH, Crepaldi L, Corsi M, Michielin F, Ferraguti F (2011) Altered levels of glutamatergic receptors and Na +/K + ATPase-α1 in the prefrontal cortex of subjects with schizophrenia. Schizophr Res 128:7–14PubMedCrossRefGoogle Scholar
  5. 5.
    El Moustaine D, Granier S, Doumazane E, Scholler P, Rahmeh R, Bron P, Mouillac B, Banères J-L, Rondard P, Pin J-P (2012) Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc Natl Acad Sci USA 109:16342–16347PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Engmann O, Hortobágyi T, Pidsley R, Troakes C, Bernstein H-G, Kreutz MR, Mill J, Nikolic M, Giese KP (2011) Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain 134:2408–2421PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Fatemi SH, Folsom TD (2014) Existence of monomer and dimer forms of mGluR5, under reducing conditions in studies of postmortem brain in various psychiatric disorders. Schizophr Res 158:270–271PubMedCrossRefGoogle Scholar
  8. 8.
    Fatemi SH, Folsom TD, Rooney RJ, Thuras PD (2013) mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 3:e271.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, Gago B, Roberts DCS, Langel U, Genedani S, Ferraro L, de la Calle A, Narvaez J, Tanganelli S, Woods A, Agnati LF (2008) Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 58:415–452PubMedCrossRefGoogle Scholar
  10. 10.
    Greenbaum D, Colangelo C, Williams K, Gerstein M (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4:117PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Han M, Newell K, Zavitsanou K, Deng C, Huang XF (2008) Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res 86:457–464PubMedCrossRefGoogle Scholar
  12. 12.
    Hu J-H, Yang L, Kammermeier PJ, Moore CG, Brakeman PR, Tu J, Yu S, Petralia RS, Li Z, Zhang P-W, Park JM, Dong X, Xiao B, Worley PF (2012) Preso1 dynamically regulates group I metabotropic glutamate receptors. Nat Neurosci 15:836–844PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Javitt DC (2012) Twenty-five years of glutamate in schizophrenia: are we there yet? Schizophr Bull 38:911–913PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kitano J, Kimura K, Yamazaki Y, Soda T, Shigemoto R, Nakajima Y, Nakanishi S (2002) Tamalin, a PDZ domain-containing protein, Links a Protein Complex Formation of Group 1 Metabotropic Glutamate Receptors and the Guanine Nucleotide Exchange Factor Cytohesins. J Neurosci 22:1280–1289PubMedGoogle Scholar
  15. 15.
    Kitano J, Yamazaki Y, Kimura K, Masukado T, Nakajima Y, Nakanishi S (2003) Tamalin is a scaffold protein that interacts with multiple neuronal proteins in distinct modes of protein-protein association. J Biol Chem 278:14762–14768PubMedCrossRefGoogle Scholar
  16. 16.
    Lee HW, Choi J, Shin H, Kim K, Yang J, Na M, Choi SY, Kang GB, Eom SH, Kim H et al (2008) Preso, a novel PSD-95-interacting FERM and PDZ domain protein that regulates dendritic spine morphogenesis. J Neurosci 28:14546–14556PubMedCrossRefGoogle Scholar
  17. 17.
    Matosin N, Frank E, Deng C, Huang X-F, Newell KA (2013) Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr Res 146:170–176PubMedCrossRefGoogle Scholar
  18. 18.
    Matosin N, Newell KA (2013) Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 37:256–268PubMedCrossRefGoogle Scholar
  19. 19.
    McCullumsmith RE, Hammond JH, Shan D, Meador-Woodruff JH (2014) Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology 39:65–87PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1–7PubMedCrossRefGoogle Scholar
  21. 21.
    Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227PubMedCrossRefGoogle Scholar
  22. 22.
    Mochizuki R, Ishizuka Y, Yanai K, Koga Y, Fukamizu A (1999) Molecular cloning and expression of human neurochondrin-1 and -2. Biochim Biophys Acta BBA 1446:397–402CrossRefGoogle Scholar
  23. 23.
    Newell KA, Matosin N (2014) Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry 14:23PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Newell KA, Matosin N, Lum JS (2014) Metabotropic glutamate receptors in the pathophysiology and treatment of schizophrenia and major depression. In: Olive MF (ed) Metabotropic glutamate receptors. Molecular mechanisms, role in neurological disorders and pharmacological effects. Nova Science, New York, pp 73–106Google Scholar
  25. 25.
    Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56:207–217PubMedCrossRefGoogle Scholar
  26. 26.
    Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates: hard cover edition, 6th edn. Academic press, LondonGoogle Scholar
  27. 27.
    Piton A, Gauthier J, Hamdan FF, Lafrenière RG, Yang Y, Henrion E, Laurent S, Noreau A, Thibodeau P, Karemera L, Spiegelman D, Kuku F, Duguay J, Destroismaisons L, Jolivet P, Côté M, Lachapelle K, Diallo O, Raymond A, Marineau C, Champagne N, Xiong L, Gaspar C, Rivière J-B, Tarabeux J, Cossette P, Krebs M-O, Rapoport JL, Addington A, DeLisi LE, Mottron L, Joober R, Fombonne E, Drapeau P, Rouleau GA (2010) Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry 16:867–880PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Radulovic J, Tronson NC (2012) Preso1, mGluR5 and the machinery of pain. Nat Neurosci 15:805–807PubMedCrossRefGoogle Scholar
  29. 29.
    Romano C, Yang W-L, O’Malley KL (1996) Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271:28612–28616PubMedCrossRefGoogle Scholar
  30. 30.
    Shinozaki K, Maruyama K, Kume H, Kuzume H, Obata K (1997) A novel brain gene, Norbin, induced by treatment of tetraethylammonium in rat hippocampal slice and accompanied with neurite-outgrowth in neuro 2a cells. Biochem Biophys Res Commun 240:766–771PubMedCrossRefGoogle Scholar
  31. 31.
    Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller H-J, Riedel M (2011) Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J Psychiatr Res 45:234–241PubMedCrossRefGoogle Scholar
  32. 32.
    Tai H-C, Besche H, Goldberg AL, Schuman EM (2010) Characterization of the brain 26S proteasome and its interacting proteins. Front Mol Neurosci 3:1–19Google Scholar
  33. 33.
    Tandon R, Nasrallah HA, Keshavan MS (2010) Schizophrenia, “just the facts” 5. treatment and prevention. Past, present, and future. Schizophr Res 122:1–23PubMedCrossRefGoogle Scholar
  34. 34.
    Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, Girirajan S, Baker C, Eichler EE, Korvatska O, Roche KW, Horwitz MS, Tsuang DW (2013) Support for the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry Chic Ill 70:582–590CrossRefGoogle Scholar
  35. 35.
    Ting JT, Peça J, Feng G (2012) functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu Rev Neurosci 35:49–71PubMedCrossRefGoogle Scholar
  36. 36.
    Volk DW, Eggan SM, Lewis DA (2010) Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am J Psychiatry 167:1489–1498PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Wang H, Nong Y, Bazan F, Greengard P, Flajolet M (2010) Norbin: a promising central nervous system regulator. Commun Integr Biol 3:487PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Wang H, Westin L, Nong Y, Birnbaum S, Bendor J, Brismar H, Nestler E, Aperia A, Flajolet M, Greengard P (2009) Norbin Is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science 326:1554–1557PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT, Newell KA, Pellen D, Huang X-F, Catts SV, Weickert TW (2012) Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry 18(11):1185–1192PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, Garrick T, Wong J, Harding AJ, Sivagnanansundaram S, Hunt C, Duncan C, Sundqvist N, Tsai SY, Anand J, Draganic D, Harper C (2010) Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 44:59–70PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Weston-Green K, Huang XF, Lian J, Deng C (2012) Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 22:364–373PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Natalie Matosin
    • 1
    • 3
    • 4
  • Francesca Fernandez-Enright
    • 1
    • 2
    • 3
    • 4
  • Samantha Jane Fung
    • 4
    • 5
    • 6
  • Jeremy Stephen Lum
    • 1
    • 3
    • 4
  • Martin Engel
    • 1
    • 3
    • 4
  • Jessica Lee Andrews
    • 1
    • 3
    • 4
  • Xu-Feng Huang
    • 1
    • 3
    • 4
  • Cynthia Shannon Weickert
    • 4
    • 5
    • 6
  • Kelly Anne Newell
    • 1
    • 3
    • 4
    Email author
  1. 1.Faculty of Science, Medicine and HealthUniversity of WollongongWollongongAustralia
  2. 2.Faculty of Social SciencesUniversity of WollongongWollongongAustralia
  3. 3.Illawarra Health and Medical Research InstituteUniversity of WollongongWollongongAustralia
  4. 4.Schizophrenia Research InstituteSydneyAustralia
  5. 5.Neuroscience Research AustraliaRandwickAustralia
  6. 6.School of PsychiatryUniversity of New South WalesRandwickAustralia

Personalised recommendations